1Lau GKK. Hepatitis B infection in china [ J ]. Clin Liver Dis, 2001,5:361 -379.
2Lok ASF, Me Mahon BJ. AASLD practice guidline: Chronic hepatitis B [ J ]. Hepatology,2007,39 : 857 - 861.
3Marcellin P, Chang TT, Lin SG, et al. Adefovir dipivoxil 437 study group. Adefovir dipivoxil for the treatment of hepatitis B antigenpositive chronic hepatitis B [ J ]. N Engl J Med,2003,348 : 808 - 816.
4Chang TT, Lai CL, Chien RN, et al. Four years of lamivudine treatment in Chinese patients with chronic hepatitis B[ J].J Gastroenterol Hepatol,2004,19 : 1276 - 1282.
5Gish R,Chang TF,de Man R,et al. Entecavir results in substantial virologic and biochemical improvement and HBeAg seroconvension through 96 weeks of treatment in HBeAg( + ) chronic hepatitis B patients( Study ETV-022 ) [ J ]. J Hepatology ,2005,42:267A.
6van Bommel F, Wunsche T, Mauss S, et al. Comparison of adefovir and tenofovir in the treatment of lamivedine resistant hepatitis B virus infection [ J ]. Hepatology, 2004,40 : 14 - 15.
7Lawrence S,Thabut D,Zoulim F, et al. Sequential treatment with lamivudine and interferon mono therapies in patents with chronic hepatitis B not responding to interferon alone: results of apilot study [ J ]. Hepatology ,2001,34:573 - 577.
8Di Bisceglie AM, Lai CL, Gane E, et al. Telbivudine Globetrialm axim al early suppression is predictive of optimal two-year efficacy in nucleoside-treated hepatitis B patients [ J ]. Hepatology, 2006, 44(Suppl) :230A - 231A.
